These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 34748813)

  • 1. Effect of polymer source variation on the properties and performance of risperidone microspheres.
    Wan B; Bao Q; Zou Y; Wang Y; Burgess DJ
    Int J Pharm; 2021 Dec; 610():121265. PubMed ID: 34748813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of polymer source on in vitro drug release from PLGA microspheres.
    Wan B; Andhariya JV; Bao Q; Wang Y; Zou Y; Burgess DJ
    Int J Pharm; 2021 Sep; 607():120907. PubMed ID: 34332059
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vitro-in vivo correlation of PLGA microspheres: Effect of polymer source variation and temperature.
    Wan B; Bao Q; Burgess DJ
    J Control Release; 2022 Jul; 347():347-355. PubMed ID: 35569590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymer source affects in vitro-in vivo correlation of leuprolide acetate PLGA microspheres.
    Wan B; Bao Q; Wang R; Burgess DJ
    Int J Pharm; 2022 Sep; 625():122032. PubMed ID: 35878870
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The effect of PLGA molecular weight differences on risperidone release from microspheres.
    Kohno M; Andhariya JV; Wan B; Bao Q; Rothstein S; Hezel M; Wang Y; Burgess DJ
    Int J Pharm; 2020 May; 582():119339. PubMed ID: 32305366
    [TBL] [Abstract][Full Text] [Related]  

  • 6. In vitro-in vivo correlation of parenteral risperidone polymeric microspheres.
    Shen J; Choi S; Qu W; Wang Y; Burgess DJ
    J Control Release; 2015 Nov; 218():2-12. PubMed ID: 26423236
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro-in vivo correlation of parenteral PLGA microspheres: Effect of variable burst release.
    Andhariya JV; Jog R; Shen J; Choi S; Wang Y; Zou Y; Burgess DJ
    J Control Release; 2019 Nov; 314():25-37. PubMed ID: 31654687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of PLGA raw materials on in vitro and in vivo performance of drug-loaded microspheres.
    Liang D; Walker J; Schwendeman PS; Chandrashekar A; Ackermann R; Olsen KF; Beck-Broichsitter M; Schwendeman SP
    Drug Deliv Transl Res; 2025 Jan; 15(1):185-202. PubMed ID: 38643259
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of formulation parameters on encapsulation efficiency and release behavior of risperidone poly(D,L-lactide-co-glycolide) microsphere.
    Su Z; Sun F; Shi Y; Jiang C; Meng Q; Teng L; Li Y
    Chem Pharm Bull (Tokyo); 2009 Nov; 57(11):1251-6. PubMed ID: 19881277
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Influence of PLGA molecular weight distribution on leuprolide release from microspheres.
    Ochi M; Wan B; Bao Q; Burgess DJ
    Int J Pharm; 2021 Apr; 599():120450. PubMed ID: 33675924
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Donepezil accelerates the release of PLGA microparticles via catalyzing the polymer degradation regardless of the end groups and molecular weights.
    Quan P; Guo W; LinYang ; Cun D; Yang M
    Int J Pharm; 2023 Feb; 632():122566. PubMed ID: 36586633
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In situ forming risperidone implants: Effect of PLGA attributes on product performance.
    Wang X; Bao Q; Wang R; Kwok O; Maurus K; Wang Y; Qin B; Burgess DJ
    J Control Release; 2023 Sep; 361():777-791. PubMed ID: 37591464
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of Manufacturing Variables and Raw Materials on the Composition-Equivalent PLGA Microspheres for 1-Month Controlled Release of Leuprolide.
    Zhou J; Walker J; Ackermann R; Olsen K; Hong JKY; Wang Y; Schwendeman SP
    Mol Pharm; 2020 May; 17(5):1502-1515. PubMed ID: 32074448
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reverse engineering of Perseris and development of compositionally equivalent formulations.
    Wang X; Bao Q; Wang R; Wan B; Wang Y; Qin B; Burgess DJ
    Int J Pharm; 2023 May; 639():122948. PubMed ID: 37044228
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of the microencapsulation method and peptide loading on poly(lactic acid) and poly(lactic-co-glycolic acid) degradation during in vitro testing.
    Witschi C; Doelker E
    J Control Release; 1998 Feb; 51(2-3):327-41. PubMed ID: 9685930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of minor manufacturing changes on stability of compositionally equivalent PLGA microspheres.
    Andhariya JV; Shen J; Wang Y; Choi S; Burgess DJ
    Int J Pharm; 2019 Jul; 566():532-540. PubMed ID: 31181309
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A reproducible accelerated in vitro release testing method for PLGA microspheres.
    Shen J; Lee K; Choi S; Qu W; Wang Y; Burgess DJ
    Int J Pharm; 2016 Feb; 498(1-2):274-82. PubMed ID: 26705156
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Development of Level A in vitro-in vivo correlations for peptide loaded PLGA microspheres.
    Andhariya JV; Jog R; Shen J; Choi S; Wang Y; Zou Y; Burgess DJ
    J Control Release; 2019 Aug; 308():1-13. PubMed ID: 31301338
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein encapsulation and release from poly(lactide-co-glycolide) microspheres: effect of the protein and polymer properties and of the co-encapsulation of surfactants.
    Blanco D; Alonso MJ
    Eur J Pharm Biopharm; 1998 May; 45(3):285-94. PubMed ID: 9653633
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Role of PLGA Variability in Controlled Drug Release from Dexamethasone Intravitreal Implants.
    Costello MA; Liu J; Kuehster L; Wang Y; Qin B; Xu X; Li Q; Smith WC; Lynd NA; Zhang F
    Mol Pharm; 2023 Dec; 20(12):6330-6344. PubMed ID: 37955890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.